Analyst firms · BofA Securities · NVAX

BofA Securities NVAX price target and rating history

Novavax Inc. (NVAX) · Health Care

BofA Securities rates Novavax Inc. (NVAX) Underperform with a $7 price target, as of its latest action on Aug 20, 2025. It has published 3 rating actions on NVAX since May 2022, including 1 upgrade and 1 downgrade.

Current rating
Underperform
Price target
$7
Median target, all firms
Too few
Actions on NVAX
3

BofA Securities price target on NVAX

$12$7.95$3.892023202420252026
BofA Securities price target on NVAX, each point a stated target, May 2022 to August 2025. Targets before May 2024 (divided by 9) are adjusted for a stock split, going by the prior target BofA Securities restated.

Every BofA Securities rating on NVAX

Questions about BofA Securities and NVAX

What is BofA Securities's price target for NVAX?
BofA Securities's latest stated price target for Novavax Inc. (NVAX) is $7, from its action on Aug 20, 2025.
What is BofA Securities's rating on NVAX?
BofA Securities rates NVAX Underperform, a bearish rating, as of Aug 20, 2025.
When did BofA Securities last change its view on NVAX?
On Aug 20, 2025, BofA Securities downgrades to Underperform from Neutral, price target $7.

More NVAX rating histories

All BofA Securities ratingsNVAX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.